<DOC>
	<DOC>NCT01497522</DOC>
	<brief_summary>The purpose of the study is to evaluate the efficacy and safety of vildagliptin 50 mg bid as an add-on therapy to metformin in Japanese patients with T2DM. This study is being conducted to support registration of the fixed-dose combination of vildagliptin and metformin for the treatment of Type 2 diabetes mellitus (T2DM) in Japan.</brief_summary>
	<brief_title>Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients with type 2 diabetes inadequately controlled with diet, exercise and oral antidiabetic therapy. HbA1c in the range of 7.010.0% Body mass index in the range 2035 kg/m2 Type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes Significant heart diseases Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Vildagliptin</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>HbA1c</keyword>
	<keyword>Fasting plasma glucose</keyword>
</DOC>